Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection

Table 1 Baseline demographic and clinical characteristics of patients with human immunodeficiency virus/hepatitis C virus co-infection that did not initiate hepatitis C virus therapy

Variable	Patients (n = 171)
Patient demographics
Age (median, IQR)	46 (39, 50)
Male gender, n (%)	126 (73.7)
Race/ethnicity, n (%)	-
Caucasian	32 (18.7)
African-American	126 (73.7)
Hispanic/other	13 (7.6)
Insurance, n (%)	-
Private	23 (13.5)
Public	67 (39.2)
None	64 (37.4)
Other	17 (9.9)
HIV clinical characteristics
HIV-1 RNA (log10 copies/mL) (median, IQR)	4.3 (2.7, 5)
CD4 (cells/μL) (median, IQR)	299 (91, 517)
HAART, n (%)	125 (73.1)
Prior AIDS-defining clinical condition, n (%)	37 (21.6)
HIV risk category, n (%)1	-
MSM	41 (24)
Injection drug use	97 (56.7)
HCV clinical characteristics
HCV RNA log10 copies/mL (median, IQR)2	5.8 (5.7, 5.8)
HCV RNA log10 (IU/mL) (median, IQR)3	6.5 (6.2, 6.7)
HCV genotype, n (%)4	-
Genotype 1	157 (91.8)
Genotype 2	8 (4.7)
Genotype 3	6 (3.5)
Genotype 4	1 (0.6)

¹HIV risk categories were not mutually exclusive;

²n = 25 patients with RNA reported as copies/mL (prior to May 1, 2007);

³n = 10 patients with RNA reported as IU/mL (following to May 1, 2007);

⁴Genotypes 1 and 2 were both reported in one patient. IQR: Interquartile range; HIV: Human immuno-deficiency virus; HCV: Hepatitis C virus; HAART: Highly active antiretroviral therapy; MSM: Men who have sex with men.